Hepatitis C inhibitor tri-peptides

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Reissue Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S312000, C514S314000, C514S339000, C514S370000, C514S425000, C546S153000, C546S159000, C546S171000, C546S175000, C546S276400, C548S517000, C548S519000, C548S523000, C548S571000

Reissue Patent

active

RE040525

ABSTRACT:
A racemate diastereoisomer and optical isomer of a compound of formula (I):wherein B is H, a C6or C10aryl, C7-16aralkyl; Het or (lower alkyl)-Het, all of which may be optionally substituted with C1-6alkyl; C1-6alkoxy; C1-6alkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with C1-6alkyl; amido; or (lower alkyl)amide; orB is an acyl derivative of formula R4—C(O)—; a carboxyl derivative of formula R4—O—C(O)—; an amide derivative of formula R4—N(R5)—C(O)—; a thioamide derivative of formula R4—N(R5)—C(S)—; or a sulfonyl of formula R4—SO2; R5is H or C1-6alkyl; andY is H or C1-6alkyl;R3is C1-8alkyl, C3-7cycloalkyl, or C4-10alkylcycloalkyl, all optionally substituted with hydroxy, C1-6alkoxy, C1-6thioalkyl, amido, (lower alkyl)amido, C6or C10aryl, or C7-16aralkyl;R2is C2—R20, NH—R20, O—R20or S—R20, wherein R20is a saturated or unsaturated C3-7cycloalkyl or C4-10(alkylcycloalkyl), all of which being optionally mono-, di- or tri-substituted with R21,or R20is a C6or C10aryl or C7-14aralkyl optionally substituted, or R20is Het or (lower alkyl)-Het, both optionally substituted, Het or (lower alkyl)-Het; carboxyl; carboxy(lower alkyl); C6or C10 aryl, C7-14aralkyl or Het, said aryl, aralkyl or Het being optionally substituted; andR1is H; C1-6alkyl, C3-7cycloalkyl, C2-6alkenyl, or C2-6alkynyl, all optionally substituted with halogen; or a pharmaceutically acceptable salt or ester thereof.

REFERENCES:
patent: 6767991 (2004-07-01), Llinas-Brunet et al.
patent: 196 00 034 (1997-07-01), None
patent: 05 155827 (1993-06-01), None
patent: WO 98 17679 (1998-04-01), None
patent: WO 99 07733 (1999-02-01), None
Gaucher et al: “Palladium (0) Catalyzed Tandem Alkylation and SN Cyclization of 1,4-Dichlorobut -2-ene by the N-(Diphenylmethylene) acetonitrile. A Stereoselective Synthesis of 1-Aminocyclo- propanecarboxylic Acids”;Tetrahedron Letters, vol. 36, No. 17,pp. 2979-2982; 1995.
Fliche, Et Al; “Enantioselective synthesis of (1R,2S) and (1S,2S) dehydrocoronamic acids”, Synthetic Communications; vol. 24, No. 20, 1994, pp. 2873-2876.
Chen, Et Al; “Chirally selective hydrolysis of D, L amino acid esters by alkaline protease”; J. Chem, Soc. Chem. Commun., vol. 20, 1986, pp. 1514-1516.
Chen, Et Al; “Kinetic resolution of esters of amino acids in t-butanol containing 5% water catalyzed by a stable industrial alkaline protease”; Chirality, vol. 6, 1994, pp. 572-576.
Linas-Brunet, M., Et Al; “Peptide-based inhibitors of the hepatitis C virus serine protease”, Bioorganic & Medicinal Chemistry Letters, vol. 8, No. 13, pp. 1713-1718; 1998.
Gershonov Et Al; “1-Aminocyclobutanecarboxylic acid derivates as novel structural elements in bioactive peptides; application to tuftsin analogs”; Journal of Medicinal Chemistry, vol. 39, No. 24, 1996, pp. 4833-4843.
Ogawa, Tomohisa Et Al; “2,3-Methanophenylalanine And.Alpha., .Beta.-Dehdrophenylalanine Derivatives As Chymotrypsin Inhibitor”; Pept. Chem. (1990), vol. 27; pp. 379-382.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Hepatitis C inhibitor tri-peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hepatitis C inhibitor tri-peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis C inhibitor tri-peptides will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3970996

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.